Clinical Trials & Research

20178 - Ph3 Vene Aza HR-MDS

A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS) (VERONA) (M15-954)

Disease Types: Myelodysplastic Syndrome,&nbs

Available at: {clinical_trial_location backspace="7"}20178 - Ph3 Vene Aza HR-MDS, {/clinical_trial_location}

Principal Investigator: {clinical_trial_principle_investi} , {/clinical_trial_principle_investi}

{clinical_trial_description}